Next Article in Journal
New Paradigm for a Targeted Cancer Therapeutic Approach: A Short Review on Potential Synergy of Gold Nanoparticles and Cold Atmospheric Plasma
Next Article in Special Issue
Hitting the Holy Grail of Hematopoietic Cell Transplantation with Naive T-Cell Depleted Allografts—Graft Engineered Hematopoietic Stem Cell Transplant
Previous Article in Journal
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
Previous Article in Special Issue
Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Biomedicines 2017, 5(3), 39; doi:10.3390/biomedicines5030039

Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?

1
Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, 2330 Shawnee Mission Pkwy., Westwood, KS 66205, USA
2
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160, USA
*
Author to whom correspondence should be addressed.
Received: 27 March 2017 / Revised: 6 June 2017 / Accepted: 14 June 2017 / Published: 1 July 2017
(This article belongs to the Special Issue Cell Therapy for the Treatment of GVHD)
View Full-Text   |   Download PDF [246 KB, uploaded 1 July 2017]   |  

Abstract

After more than a decade of preclinical and clinical development, therapeutic infusion of mesenchymal stromal cells is now a leading investigational strategy for the treatment of acute graft-versus-host disease (GVHD). While their clinical use continues to expand, it is still unknown which of their immunomodulatory properties contributes most to their therapeutic activity. Herein we describe the proposed mechanisms, focusing on the inhibitory activity of mesenchymal stromal cells (MSCs) at immunologic checkpoints. A deeper understanding of the mechanism of action will allow us to design more effective treatment strategies. View Full-Text
Keywords: cell- and tissue-based therapy; exosomes; graft vs. host disease; immunotherapy; adoptive; mesenchymal stromal cells; transplantation immunology cell- and tissue-based therapy; exosomes; graft vs. host disease; immunotherapy; adoptive; mesenchymal stromal cells; transplantation immunology
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Dunavin, N.; Dias, A.; Li, M.; McGuirk, J. Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease? Biomedicines 2017, 5, 39.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top